China: Food and Drugs Law

Earlier this year, the Commission relied for the first time on the EU's International Procurement Instrument in order to take measures against China for its failure to ensure reciprocal access to public...

2022年5月9日，国家药监局发布《药品管理法实施条例（修订草案征求意见稿）》（简称"《征求意见稿》"），向社会公开征求意见，征求意见反馈截止

2022年4月11日，国家药品监督管理局（" 国家药监局"）发布了《药品年度报告管理规定》以及相应的报告模板（以下合称" 《年报规定》"）...

"不竞争条款（Non-Compete Clause）"是License-in/out交易中保障技术价值、

License-in/out transactions have become a key strategic approach for innovative drug and medical device (including medical aesthetics) companies to expedite the research and development of the products and expand market presence.

On November 13, 2024, the National Medical Products Administration (the "NMPA") issued the Interim Provisions on the Management of Domestic Responsible Entity Designated by Overseas Marketing Authorization Holders (hereinafter referred to as the "Regulations on Domestic Responsible Entities").

On December 1, 2019, the Drug Administration Law and the Vaccine Administration Law officially came into effect, and the relevant regulations adjusted the management...

In the upcoming 2023, the life sciences and medical health fields have ushered in many developments and have become the basic core areas related to national security...

On September 8, 2023, the China Biotechnology Development Center directly under the Ministry of Science and Technology of the People's Republic of China...